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BACKGROUND
Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) 
that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), with in-
creased activity in tumors that express programmed death ligand 1 (PD-L1).
METHODS
In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously 
untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no 
sensitizing mutation of the epidermal growth factor receptor gene or translocation of 
the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose 
of 200 mg every 3 weeks) or the investigator’s choice of platinum-based chemotherapy. 
Crossover from the chemotherapy group to the pembrolizumab group was permitted in 
the event of disease progression. The primary end point, progression-free survival, was 
assessed by means of blinded, independent, central radiologic review. Secondary end 
points were overall survival, objective response rate, and safety.
RESULTS
Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to 
not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the 
chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 
0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pem-
brolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 
95% CI, 0.41 to 0.89; P = 0.005). The response rate was higher in the pembrolizumab 
group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of re-
sponse was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ 
to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring 
in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events 
(26.6% vs. 53.3%).
CONCLUSIONS
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, 
pembrolizumab was associated with significantly longer progression-free and overall 
survival and with fewer adverse events than was platinum-based chemotherapy. (Funded 
by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738.)
a bs tr ac t
Pembrolizumab versus Chemotherapy for PD-L1–Positive 
Non–Small-Cell Lung Cancer
Martin Reck, M.D., Ph.D., Delvys Rodríguez-Abreu, M.D., Andrew G. Robinson, M.D., Rina Hui, M.B., B.S., Ph.D., 
Tibor Csőszi, M.D., Andrea Fülöp, M.D., Maya Gottfried, M.D., Nir Peled, M.D., Ph.D., Ali Tafreshi, M.D., 
Sinead Cuffe, M.D., Mary O’Brien, M.D., Suman Rao, M.D., Katsuyuki Hotta, M.D., Ph.D., Melanie A. Leiby, Ph.D., 
Gregory M. Lubiniecki, M.D., Yue Shentu, Ph.D., Reshma Rangwala, M.D., Ph.D., and Julie R. Brahmer, M.D.,  
for the KEYNOTE-024 Investigators* 
The New England Journal of Medicine 
Downloaded from nejm.org at QUEENSLAND UNIVERSITY OF TECHNOLOGY on January 30, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;19 nejm.org November 10, 20161824
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
A pproximately 23 to 28% of patients with advanced non–small-cell lung cancer (NSCLC) have a high level of programmed 
death ligand 1 (PD-L1) expression, which is de-
fined as membranous PD-L1 expression on at 
least 50% of tumor cells, regardless of the stain-
ing intensity (i.e., a PD-L1 tumor proportion 
score of 50% or greater).1,2 Data from the phase 1 
KEYNOTE-001 and phase 3 KEYNOTE-010 stud-
ies indicated that patients with advanced NSCLC 
and a PD-L1 tumor proportion score of 50% or 
greater were more likely than those with lower 
tumor proportion scores to have a response to 
pembrolizumab, a highly selective, humanized 
monoclonal antibody against programmed death 1 
(PD-1) that prevents PD-1 from engaging PD-L1 
and PD-L2.1-3
Current first-line treatment decisions for ad-
vanced NSCLC are based on the presence of ge-
netic aberrations, such as sensitizing mutations 
of epidermal growth factor receptor (EGFR) and 
translocations of anaplastic lymphoma kinase 
(ALK). However, most patients with NSCLC do 
not harbor these oncogenic drivers, and for 
these patients, treatment options are limited to 
cytotoxic chemotherapy. In patients enrolled in 
the KEYNOTE-001 trial who had previously un-
treated NSCLC and a PD-L1 tumor proportion 
score of 50% or greater, pembrolizumab (ad-
ministered every 2 or 3 weeks at a dose of 10 mg 
per kilogram of body weight) was associated with 
a response rate of 58.3%, median progression-
free survival of 12.5 months, and 24-month 
overall survival of 60.6%.4
In the international, randomized, open-label, 
phase 3 KEYNOTE-024 trial, we compared pem-
brolizumab (administered at a fixed dose of 
200 mg every 3 weeks) with the investigator’s 
choice of cytotoxic chemotherapy as first-line 
therapy for patients with advanced NSCLC and a 
PD-L1 tumor proportion score of 50% or greater.
Me thods
Patients
Patients 18 years of age or older were eligible for 
enrollment if they had histologically or cytologi-
cally confirmed stage IV NSCLC with no sensi-
tizing EGFR mutations or ALK translocations, had 
undergone no previous systemic therapy for 
metastatic disease, and had an Eastern Coopera-
tive Oncology Group (ECOG) performance-status 
score of 0 or 1 (on a 5-point scale, with 0 indi-
cating no symptoms and higher scores indicat-
ing increasing disability), at least one measur-
able lesion according to Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1,5 
a life expectancy of at least 3 months, and a PD-L1 
tumor proportion score of 50% or greater. Pa-
tients were ineligible if they were receiving sys-
temic glucocorticoids (excluding daily glucocor-
ticoid-replacement therapy for conditions such 
as adrenal or pituitary insufficiency) or other 
immunosuppressive treatment or if they had 
untreated brain metastases, active autoimmune 
disease for which they had received systemic treat-
ment during the previous 2 years, active intersti-
tial lung disease, or a history of pneumonitis for 
which they had received glucocorticoids.
Trial Design and Treatment
Patients were randomly assigned, in a 1:1 ratio, 
to receive treatment with either pembrolizumab 
(administered intravenously at a dose of 200 mg 
every 3 weeks) for 35 cycles or the investigator’s 
choice of one of the following five platinum-
based chemotherapy regimens for 4 to 6 cycles: 
carboplatin plus pemetrexed, cisplatin plus peme-
trexed, carboplatin plus gemcitabine, cisplatin 
plus gemcitabine, or carboplatin plus paclitaxel 
(Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
Chemotherapy regimens that included peme-
trexed were permitted only for patients who had 
nonsquamous tumors; these patients could con-
tinue to receive pemetrexed as maintenance ther-
apy after the completion of combination chemo-
therapy. The intended chemotherapy regimen, 
including the use of pemetrexed maintenance 
therapy, was chosen before the patient under-
went randomization. Randomization was strati-
fied by ECOG performance-status score (0 vs. 1), 
tumor histologic type (squamous vs. nonsqua-
mous), and region of enrollment (East Asia vs. 
non–East Asia) and did not include any provisions 
regarding equal distribution of enrollment across 
participating sites or stratification by site. Treat-
ment was continued for the specified number of 
cycles or until the patient had radiologic disease 
progression (defined according to RECIST; Table 
S2 in the Supplementary Appendix), had treat-
ment-related adverse events of unacceptable sever-
ity, or withdrew consent or until the investigator 
decided to withdraw the patient, whichever oc-
curred first. Patients in the chemotherapy group 
who had disease progression, which was verified 
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by means of blinded, independent, central radio-
logic review, could cross over to receive pembro-
lizumab, if safety criteria were met. There was 
no preplanned crossover from the pembrolizu-
mab group to the chemotherapy group, and there 
were no guidelines regarding therapy after dis-
ease progression for patients in the pembroli-
zumab group. Patients in either treatment group 
who were in clinically stable condition and were 
considered by the investigator to be deriving 
clinical benefit could continue therapy after dis-
ease progression. Full guidance on treatment 
decisions, including the management of adverse 
events, can be found in the trial protocol, avail-
able at NEJM.org.
Trial Assessments
PD-L1 expression was assessed in formalin-fixed 
tumor samples at a central laboratory with the 
use of the commercially available PD-L1 IHC 
22C3 pharmDx assay (Dako North America).6,7 
Tumor samples were obtained by core-needle or 
excisional biopsy or from tissue resected at the 
time the metastatic disease was diagnosed. Fine-
needle aspirates or samples obtained from irra-
diated sites or before the administration of adju-
vant or neoadjuvant therapy were not permitted 
to be used. Imaging studies of the tumors were 
obtained every 9 weeks, and the response to 
treatment was assessed according to RECIST by 
means of blinded, independent, central radio-
logic review. Adverse events were reviewed, a 
physical examination was performed, and vital 
signs, a complete blood count with a differential 
count, and a comprehensive blood panel were 
assessed every 3 weeks during treatment and at 
the time of treatment discontinuation; T3, free 
T4, and thyrotropin were assessed every 6 weeks. 
During the survival follow-up phase, patients 
were contacted every 2 months for an assess-
ment of survival. The full assessment schedule is 
available in the trial protocol. All adverse events 
and abnormalities were graded according to the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0.
End Points
The primary end point was progression-free sur-
vival, which was defined as the time from ran-
domization to disease progression or death from 
any cause. Secondary end points included overall 
survival, which was defined as the time from 
randomization to death from any cause; objec-
tive response rate, which was defined as the per-
centage of patients with a confirmed complete 
or partial response; and safety. An exploratory 
end point was duration of response, which was 
defined as the time from the first documenta-
tion of a complete or partial response to disease 
progression. A full list of end points is available 
in the protocol. Efficacy was assessed in the 
intention-to-treat population, which included all 
patients who underwent randomization. Safety 
was assessed in the as-treated population, which 
included all patients who received at least one 
dose of the assigned trial treatment.
Trial Oversight
The KEYNOTE-024 trial was designed by Merck 
representatives and academic advisors. Data were 
collected by investigators and associated site 
personnel, analyzed by statisticians employed by 
Merck, and interpreted by academic authors and 
Merck representatives. An external data and safety 
monitoring committee oversaw the trial and as-
sessed the safety and efficacy at prespecified 
interim analyses. Committee members are listed 
in the Supplementary Appendix.
The trial protocol and all amendments were 
approved by the appropriate institutional review 
board or independent ethics committee at each 
trial center. The trial was conducted in accor-
dance with Good Clinical Practice guidelines 
and the provisions of the Declaration of Helsinki. 
All the patients provided written informed con-
sent before enrollment.
All the authors had full access to the data, 
vouch for the completeness and accuracy of the 
data, and attest that the trial was conducted in 
accordance with the protocol and all amend-
ments. The first draft of the manuscript was 
written by the first and last authors with input 
from authors employed by Merck. All the authors 
participated in reviewing and editing the manu-
script, and approved the submitted draft. As part 
of the site agreement signed before trial partici-
pation, investigators agreed to keep all aspects of 
the trial, including the resultant data, confidential.
Statistical Analysis
The Kaplan–Meier method was used to estimate 
progression-free and overall survival. For the 
analysis of progression-free survival, data for 
patients who were alive and had no disease pro-
gression or who were lost to follow-up were 
censored at the time of the last tumor assess-
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ment. For the analysis of overall survival, data 
for patients who were alive or who were lost to 
follow-up were censored at the time of the last 
contact. Between-group differences in progression-
free and overall survival were assessed with the 
use of a stratified log-rank test. Hazard ratios 
and associated 95% confidence intervals were 
assessed with the use of a stratified Cox propor-
tional-hazards model with Efron’s method of 
handling ties. The same stratification factors 
used for randomization were applied to the 
stratified log-rank and Cox models. Differences 
in response rate were assessed with the use of the 
stratified method of Miettinen and Nurminen.
The overall type I error rate for this trial was 
strictly controlled at a one-sided alpha level of 
2.5%. The full statistical analysis plan is avail-
able in the protocol. The protocol specified two 
interim analyses before the final analysis. The 
first interim analysis was to be performed after 
the first 191 patients who underwent random-
ization had a minimum of 6 months of follow-
up; at this time, the objective response rate 
would be analyzed at an alpha level of 0.5%. The 
primary objective of the second interim analysis, 
which was to be performed after approximately 
175 events of progression or death had been ob-
served, was to evaluate the superiority of pem-
brolizumab over chemotherapy with respect to 
progression-free survival, at a one-sided alpha 
level of 2.0%. If pembrolizumab was superior 
with respect to progression-free survival, the 
superiority of pembrolizumab over chemotherapy 
with respect to overall survival would be as-
sessed by means of a group-sequential test with 
two analyses, to be performed after approxi-
mately 110 and 170 deaths had been observed. 
We calculated that with approximately 175 events 
of progression or death, the trial would have 
97% power to detect a hazard ratio for progres-
sion or death with pembrolizumab versus chemo-
therapy of 0.55. At the time of the second in-
terim analysis, the trial had approximately 40% 
power to detect a hazard ratio for death with 
pembrolizumab versus chemotherapy of approx-
imately 0.65 at a one-sided alpha level of 1.18%.
The second interim analysis was performed 
after 189 events of progression or death and 108 
deaths had occurred and was based on a cutoff 
date of May 9, 2016. The data and safety moni-
toring committee reviewed the results on June 8, 
2016, and June 14, 2016. Because pembrolizumab 
was superior to chemotherapy with respect to 
overall survival at the prespecified multiplicity-
adjusted, one-sided alpha level of 1.18%, the 
external data and safety monitoring committee 
recommended that the trial be stopped early to 
give the patients who were receiving chemo-
therapy the opportunity to receive pembrolizu-
mab. All data reported herein are based on the 
second interim analysis.
R esult s
Patient Characteristics and Treatment
A total of 1934 patients at 142 sites in 16 coun-
tries were screened for enrollment, including 
1729 who submitted samples for PD-L1 assess-
ment (Fig. S1 in the Supplementary Appendix). 
Of the 1653 patients whose samples could be 
evaluated for PD-L1, 500 (30.2%) had a PD-L1 
tumor proportion score of 50% or greater. Be-
tween September 19, 2014, and October 29, 2015, 
a total of 305 patients at 102 sites who met inclu-
sion criteria were randomly assigned to either 
the pembrolizumab group (154 patients) or the 
chemotherapy group (151 patients). In the chemo-
therapy group, the most common regimen was 
carboplatin plus pemetrexed (in 67 patients). All 
the patients in the pembrolizumab group re-
ceived the trial treatment. In the chemotherapy 
group, 1 patient withdrew consent before receiv-
ing the planned trial treatment, and 46 patients 
received pemetrexed maintenance therapy after 
completion of combination chemotherapy. The 
demographic characteristics of the patients and 
the disease characteristics at baseline were gen-
erally well balanced between treatment groups 
(Table 1), although more patients in the chemo-
therapy group than in the pembrolizumab group 
had never smoked (12.6% vs. 3.2%) and more 
patients in the pembrolizumab group than in 
the chemotherapy group had brain metastases 
(11.7% vs. 6.6%). These differences were not 
statistically significant.
As of May 9, 2016, the median duration of 
follow-up was 11.2 months (range, 6.3 to 19.7), 
and 48.1% of the patients in the pembrolizumab 
group and 10.0% of the patients in the chemo-
therapy group were still receiving the assigned 
treatment (Fig. S1 in the Supplementary Appendix). 
The median duration of treatment was 7.0 months 
(range, 1 day to 18.7 months) in the pembroli-
zumab group and 3.5 months (range, 1 day to 
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16.8 months) in the chemotherapy group. The 
median number of treatment cycles in the pem-
brolizumab group was 10.5 (range, 1 to 26); the 
median number in the chemotherapy group was 
4 (range, 1 to 6), both for patients who had 
squamous tumors and for those who had non-
squamous tumors. In the chemotherapy group, 
66 patients (43.7%) crossed over to receive pem-
brolizumab after disease progression. Of the pa-
tients who crossed over, 57.6% were still receiving 
pembrolizumab at the time of data cutoff.
Progression-free Survival
In the intention-to-treat population, on the ba-
sis of 189 total events of progression or death, 
median progression-free survival was 10.3 months 
(95% confidence interval [CI], 6.7 to not reached) 
in the pembrolizumab group and 6.0 months 
(95% CI, 4.2 to 6.2) in the chemotherapy group 
(Fig. 1A). The estimated percentage of patients 
who were alive and had no disease progression 
at 6 months was 62.1% (95% CI, 53.8 to 69.4) in 
the pembrolizumab group and 50.3% (95% CI, 
41.9 to 58.2) in the chemotherapy group. Pro-
gression-free survival was significantly longer in 
the pembrolizumab group than in the chemo-
therapy group (hazard ratio for disease progres-
sion or death, 0.50; 95% CI, 0.37 to 0.68; 
P<0.001). The benefit of pembrolizumab with 
respect to progression-free survival was evident 
in all subgroups examined (Fig. 1B).
Overall Survival
At the time of the second interim analysis, 108 
deaths had occurred. The estimated percentage 
of patients who were alive at 6 months was 80.2% 
(95% CI, 72.9 to 85.7) in the pembrolizumab 
group and 72.4% (95% CI, 64.5 to 78.9) in the 
Characteristic
Pembrolizumab Group 
(N = 154)
Chemotherapy Group 
(N = 151)
Age — yr
Median 64.5 66.0
Range 33–90 38–85
Male sex — no. (%) 92 (59.7) 95 (62.9)
Region of enrollment — no. (%)
East Asia 21 (13.6) 19 (12.6)
Non–East Asia 133 (86.4) 132 (87.4)
ECOG performance-status score — no. (%)†
0 54 (35.1) 53 (35.1)
1 99 (64.3) 98 (64.9)
Smoking status — no. (%)
Current 34 (22.1) 31 (20.5)
Former 115 (74.7) 101 (66.9)
Never 5 (3.2) 19 (12.6)
Histology — no. (%)
Squamous 29 (18.8) 27 (17.9)
Nonsquamous 125 (81.2) 124 (82.1)
Brain metastases — no. (%) 18 (11.7) 10 (6.6)
Previous systemic neoadjuvant therapy — no. (%) 3 (1.9) 1 (0.7)
Previous systemic adjuvant therapy — no. (%) 6 (3.9) 3 (2.0)
*  The intention-to-treat population included all patients who underwent randomization. There were no significant differ-
ences between treatment groups.
†  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symp-
toms and higher scores indicating increasing disability. One patient (0.6%), who was in the pembrolizumab group, had 
an ECOG performance-status score of 2.
Table 1. Baseline Demographic and Disease Characteristics of Patients in the Intention-to-Treat Population.*
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B
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≥65 yr
Sex
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Female
Region of enrollment
East Asia
Non–East Asia
ECOG performance-status score
0
1
Histologic type
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Nonsquamous
Smoking status
Current
Former
Never
Brain metastases at baseline
Yes
No
Platinum-based chemotherapy regimen
Included pemetrexed
Did not include pemetrexed
189/305
  91/141
  98/164
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21/40
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0.55 (0.20–1.56)
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0.63 (0.44–0.91)
0.29 (0.17–0.50)
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0.50 (95% CI, 0.37–0.68)
 P<0.001
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chemotherapy group (Fig. 2); median overall 
survival was not reached in either group. Overall 
survival was significantly longer in the pembro-
lizumab group than in the chemotherapy group 
(hazard ratio for death, 0.60; 95% CI, 0.41 to 
0.89; P = 0.005).
Objective Response Rate
The objective response rate, assessed according 
to RECIST, was 44.8% (95% CI, 36.8 to 53.0) in 
the pembrolizumab group and 27.8% (95% CI, 
20.8 to 35.7) in the chemotherapy group (Table 2). 
The median time to response was 2.2 months in 
both groups. The median duration of response 
was not reached (range, 1.9+ to 14.5+ months) 
in the pembrolizumab group and was 6.3 months 
(range, 2.1+ to 12.6+) in the chemotherapy group. 
(Plus signs in the ranges indicate the response 
was ongoing at cutoff.)
Adverse Events
During treatment with the initially assigned 
therapy, treatment-related adverse events occurred 
in 73.4% of the patients in the pembrolizumab 
group and in 90.0% of the patients in the che-
motherapy group (Table 3). Grade 3, 4, or 5 
treatment-related adverse events occurred in twice 
as many patients in the chemotherapy group as 
in the pembrolizumab group (53.3% vs. 26.6%). 
Serious treatment-related adverse events occurred 
in a similar percentage of patients in the pem-
brolizumab group and the chemotherapy group 
(21.4% and 20.7%, respectively). Discontinuation 
of treatment because of treatment-related adverse 
events occurred in 7.1% of patients in the pem-
brolizumab group and in 10.7% of patients in the 
chemotherapy group. Treatment-related adverse 
events that led to death occurred in one patient 
in the pembrolizumab group (sudden death of 
unknown cause on day 2) and three patients in 
the chemotherapy group (one death due to pul-
monary sepsis on day 25, one death due to 
pulmonary alveolar hemorrhage on day 112, and 
one death of unknown cause on day 8).
The most common treatment-related adverse 
events were diarrhea (in 14.3% of the patients), 
fatigue (10.4%), and pyrexia (10.4%) in the pem-
brolizumab group and anemia (44.0%), nausea 
(43.3%), and fatigue (28.7%) in the chemotherapy 
group (Table 3). Grade 3, 4, or 5 treatment-related 
adverse events that occurred in four or more 
patients were diarrhea (in 3.9% of the patients) 
and pneumonitis (2.6%) in the pembrolizumab 
group and anemia (19.3%), neutropenia (13.3%), 
decreased platelet count (6.0%), thrombocytope-
nia (5.3%), decreased neutrophil count (4.0%), 
Figure 1 (facing page). Progression-free Survival  
in the Intention-to-Treat Population.
Panel A shows Kaplan–Meier estimates of progression-
free survival, according to treatment group. Tick marks 
represent data censored at the last time the patient 
was known to be alive and without disease progression. 
Panel B shows the analysis of progression-free survival 
in key subgroups. Progression-free survival was assessed 
according to Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1, by means of blinded, indepen-
dent, central radiologic review. The intention-to-treat 
population included all patients who underwent ran-
domization. Eastern Cooperative Oncology Group 
(ECOG) performance-status scores range from 0 to 5, 
with 0 indicating no symptoms and higher scores in-
dicating increasing disability. The subgroups for the 
platinum-based chemotherapy regimen are based on 
the regimen chosen before the patient was randomly 
assigned to treatment with either pembrolizumab or 
platinum-based chemotherapy.
Figure 2. Overall Survival in the Intention-to-Treat Population.
Shown are Kaplan–Meier estimates of overall survival, according to treatment 
group. Tick marks represent data censored at the last time the patient was 
known to be alive. The intention-to-treat population included all patients 
who underwent randomization.
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fatigue (3.3%), and decreased appetite (2.7%) in 
the chemotherapy group. Although decreased 
neutrophil count and neutropenia may reflect the 
same condition, they were listed by the investi-
gators as two distinct events; this is also the 
case for decreased platelet count and thrombo-
cytopenia.
Immune-mediated adverse events, both those 
that were and those that were not attributed by 
the investigator to treatment, occurred in 29.2% 
of patients in the pembrolizumab group and in 
4.7% of patients in the chemotherapy group; 
grade 3 or 4 immune-mediated events occurred 
in 9.7% and 0.7% of patients, respectively (Ta-
ble 3). The only grade 3 or 4 immune-mediated 
events that occurred in two or more patients 
occurred in the pembrolizumab group: severe 
skin reactions (in 3.9%), pneumonitis (2.6%), and 
colitis (1.3%). There were no grade 5 immune-
mediated events.
Discussion
The results of this randomized trial showed the 
superiority of anti–PD-1 therapy over platinum-
based combination chemotherapy as first-line 
treatment for advanced NSCLC with PD-L1 ex-
pression on at least 50% of tumor cells and with 
no sensitizing EGFR mutations or ALK transloca-
tions. First-line treatment with pembrolizumab 
resulted in significantly longer progression-free 
and overall survival than did standard chemo-
therapy, which included the use of pemetrexed 
maintenance therapy for patients with nonsqua-
mous tumors. The magnitude of benefit observed 
in the chemotherapy group is consistent with 
that previously observed with platinum-based 
combination regimens and pemetrexed mainte-
nance therapy.8-10 The longer progression-free 
survival with pembrolizumab than with chemo-
therapy was observed across all subgroups ana-
lyzed and thus appeared to occur independently 
of patient age, sex, ECOG performance-status 
score, tumor histologic type, region of enroll-
ment, presence or absence of brain metastases at 
baseline, chemotherapy regimen administered, 
and smoking status, although the low number of 
patients who had never smoked (24 patients) 
precludes accurate interpretation of the benefit 
in this population. The benefit of pembrolizu-
mab observed in patients who had squamous 
tumors is notable, given the limited treatment 
options available for these patients. Pembrolizu-
mab was also associated with a higher objective 
response rate, a longer duration of response, and 
a lower frequency of treatment-related adverse 
events than was chemotherapy.
Pembrolizumab was associated with signifi-
cantly longer overall survival than was chemo-
therapy, despite the low number of deaths ob-
served and the potentially confounding effect of 
crossover from the chemotherapy group to the 
pembrolizumab group. On the basis of data 
from the second interim analysis, the data and 
safety monitoring committee recommended that 
the trial be stopped and that patients remaining 
in the chemotherapy group be offered pembroli-
zumab. At the time of data cutoff, 35.4% of the 
enrolled patients had died and 43.7% of the pa-
tients in the chemotherapy group had crossed 
over to receive pembrolizumab. These data un-
derscore the substantial benefit of pembrolizu-
mab as initial therapy for advanced NSCLC with 
PD-L1 expression on at least 50% of tumor cells.
All the patients enrolled in this study had a 
PD-L1 tumor proportion score of 50% or greater. 
The 50% cutoff was established on the basis of 
data from the KEYNOTE-001 trial that showed 
Variable
Pembrolizumab  
Group 
(N = 154)
Chemotherapy  
Group 
(N = 151)
Objective response†
No. of patients 69 42
% (95% CI) 44.8 (36.8 to 53.0) 27.8 (20.8 to 35.7)
Time to response — mo‡
Median 2.2 2.2
Range 1.4 to 8.2 1.8 to 12.2
Duration of response — mo‡§
Median NR 6.3
Range 1.9+ to 14.5+ 2.1+ to 12.6+
*  The intention-to-treat population included all patients who underwent random-
ization. NR denotes not reached.
†  Objective response was considered to be a confirmed complete or partial 
 response, as assessed by means of blinded, independent, central radiologic 
review according to Response Evaluation Criteria in Solid Tumors, version 1.1. 
The estimated difference between the pembrolizumab group and the chemo-
therapy group, which was assessed with the use of the stratified method of 
Miettinen and Nurminen, was 16.6 percentage points (95% CI, 6.0 to 27.0).
‡  Time to response and duration of response were evaluated in the patients who 
had an objective response (69 patients in the pembrolizumab group and 42 in 
the chemotherapy group).
§  Duration of response was calculated with the use of the Kaplan–Meier method 
for censored data. Plus signs in the ranges indicate the response was ongoing 
at cutoff.
Table 2. Summary of Response in the Intention-to-Treat Population.*
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Adverse Event
Pembrolizumab Group 
(N = 154)
Chemotherapy Group 
 (N = 150)
Any Grade Grade 3, 4, or 5 Any Grade Grade 3, 4, or 5
number of patients (percent)
Treatment-related†
Any 113 (73.4) 41 (26.6) 135 (90.0) 80 (53.3)
Serious 33 (21.4) 29 (18.8) 31 (20.7) 29 (19.3)
Led to discontinuation 11 (7.1) 8 (5.2) 16 (10.7) 9 (6.0)
Led to death 1 (0.6) 1 (0.6) 3 (2.0) 3 (2.0)
Occurred in ≥10% of patients in either 
group‡
Nausea 15 (9.7) 0 65 (43.3) 3 (2.0)
Anemia 8 (5.2) 3 (1.9) 66 (44.0) 29 (19.3)
Fatigue 16 (10.4) 2 (1.3) 43 (28.7) 5 (3.3)
Decreased appetite 14 (9.1) 0 39 (26.0) 4 (2.7)
Diarrhea 22 (14.3) 6 (3.9) 20 (13.3) 2 (1.3)
Neutropenia 1 (0.6) 0 34 (22.7) 20 (13.3)
Vomiting 4 (2.6) 1 (0.6) 30 (20.0) 1 (0.7)
Pyrexia 16 (10.4) 0 8 (5.3) 0
Constipation 6 (3.9) 0 17 (11.3) 0
Stomatitis 4 (2.6) 0 18 (12.0) 2 (1.3)
Decreased neutrophil count 0 0 20 (13.3) 6 (4.0)
Increased blood creatinine level 3 (1.9) 0 15 (10.0) 1 (0.7)
Decreased platelet count 0 0 18 (12.0) 9 (6.0)
Thrombocytopenia 0 0 17 (11.3) 8 (5.3)
Decreased white-cell count 1 (0.6) 0 16 (10.7) 3 (2.0)
Dysgeusia 1 (0.6) 0 15 (10.0) 0
Immune-mediated§
Any 45 (29.2) 15 (9.7) 7 (4.7) 1 (0.7)
Hypothyroidism 14 (9.1) 0 2 (1.3) 0
Hyperthyroidism 12 (7.8) 0 2 (1.3) 0
Pneumonitis 9 (5.8) 4 (2.6) 1 (0.7) 1 (0.7)
Infusion reaction 7 (4.5) 0 2 (1.3) 0
Severe skin reaction 6 (3.9) 6 (3.9) 0 0
Thyroiditis 4 (2.6) 0 0 0
Colitis 3 (1.9) 2 (1.3) 0 0
Myositis 3 (1.9) 0 0 0
Hypophysitis 1 (0.6) 1 (0.6) 0 0
Nephritis 1 (0.6) 1 (0.6) 0 0
Pancreatitis 1 (0.6) 1 (0.6) 0 0
Type 1 diabetes mellitus 1 (0.6) 1 (0.6) 0 0
*  The as-treated population included all patients who received at least one dose of a trial treatment. For the patients in 
the chemotherapy group who crossed over to the pembrolizumab group after disease progression, only events that 
 occurred during treatment with the assigned chemotherapy regimen are included.
†  Events were attributed to treatment by the investigator and are listed as indicated by the investigator on the case-report 
form. Although decreased neutrophil count and neutropenia may reflect the same condition, they were listed by the in-
vestigators as two distinct events; this is also the case for decreased platelet count and thrombocytopenia.
‡  Events are listed in descending order of frequency in the total population.
§  The immune-mediated events, both those that were and those that were not attributed to study treatment by the inves-
tigator, are listed in descending order of frequency in the pembrolizumab group. In addition to specific preferred terms, 
related terms are also included.
Table 3. Adverse Events in the As-Treated Population.*
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a significantly increased objective response rate 
in this population.2 The prevalence of a tu-
mor proportion score of 50% or greater in the 
KEYNOTE-024 screened population (30.2%) was 
consistent with the prevalence observed in the 
KEYNOTE-001 trial among previously untreated 
patients (24.9%) and in the KEYNOTE-010 trial 
among previously treated patients (28%).1,2 On-
going phase 3 studies, such as KEYNOTE-042 
(ClinicalTrials.gov number, NCT02220894), will 
assess the benefit of pembrolizumab over chemo-
therapy in previously untreated patients who 
have a tumor proportion score of 1% or greater.
In the KEYNOTE-024 trial, pembrolizumab 
was administered at a fixed dose. Pharmacoki-
netic modeling suggested that a 200-mg fixed 
dose of pembrolizumab would provide exposure 
similar to the weight-based dosing regimens 
used in previous studies of pembrolizumab.11 
The progression-free survival, overall survival, 
objective response rate, and duration of response 
observed in the pembrolizumab group in this 
trial are consistent with those observed in pa-
tients enrolled in the KEYNOTE-001 trial who 
had previously untreated NSCLC with a PD-L1 
tumor proportion score of 50% or greater and 
who were treated with pembrolizumab at a dose 
of 10 mg per kilogram4; these results suggest 
that 200 mg is an appropriate dose of pembroli-
zumab for this patient population.
The safety profile of pembrolizumab observed 
in this trial was consistent with that seen previ-
ously with pembrolizumab for the treatment of 
advanced NSCLC1,2 and other tumor types.12-16 
The safety profile of chemotherapy was also as 
expected. Immune-mediated adverse events (in-
cluding pneumonitis) occurred more frequently 
in the pembrolizumab group than in the chemo-
therapy group, whereas cytopenias occurred more 
frequently in the chemotherapy group than in the 
pembrolizumab group; these results are consis-
tent with the mechanism of action for each 
therapy. Most immune-mediated events were of 
grade 1 or 2 severity, and none led to death. 
However, the overall safety profile appeared to 
be better with pembrolizumab than with chemo-
therapy.
In conclusion, the results of the KEYNOTE-024 
trial showed that pembrolizumab was associated 
with longer progression-free and overall survival 
and fewer treatment-related adverse events than 
was platinum-based combination chemotherapy 
in patients with previously untreated advanced 
NSCLC and a PD-L1 tumor proportion score of 
50% or greater.
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